Lisata Therapeutics’ (LSTA) Hold Rating Reaffirmed at Brookline Capital Management

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “hold” rating restated by Brookline Capital Management in a research note issued on Wednesday,Benzinga reports.

LSTA has been the topic of several other reports. Zacks Research downgraded Lisata Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $23.50.

Lisata Therapeutics Stock Up 86.8%

Shares of NASDAQ LSTA traded up $1.88 during trading on Wednesday, reaching $4.04. The company had a trading volume of 4,129,794 shares, compared to its average volume of 352,753. Lisata Therapeutics has a 12-month low of $1.81 and a 12-month high of $4.04. The business’s 50-day moving average is $2.03 and its 200 day moving average is $2.32. The stock has a market cap of $35.59 million, a PE ratio of -1.89 and a beta of 1.11.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.05. On average, analysts anticipate that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC purchased a new position in shares of Lisata Therapeutics during the second quarter worth $32,000. Ground Swell Capital LLC acquired a new stake in Lisata Therapeutics in the 3rd quarter worth about $62,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Lisata Therapeutics during the third quarter worth approximately $37,000. 8.94% of the stock is currently owned by institutional investors and hedge funds.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.